Primary prevention of uterine cervix cancer: Focus on vaccine history and current strategy

Obstetrics and Gynecology Clinics of North America

Volumn 29, Issue 4, 2002, Pages 843-868

  Tewari, Krishnansu Sujata ^a   DiSaia, Philip John ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; RETINOIC ACID; TRACE ELEMENT;

ANIMAL MODEL; CANCER EPIDEMIOLOGY; ERADICATION THERAPY; FEMALE; HISTORY OF MEDICINE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; PRIORITY JOURNAL; REVIEW; SMALLPOX; SOCIOECONOMICS; UTERINE CERVIX CANCER; VACCINATION; VIRUS INFECTION; VIRUS ONCOGENE; WART VIRUS; ZOONOSIS;

FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VIRAL VACCINES;

EID: 0036928588     PISSN: 08898545     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8545(02)00046-3     Document Type: Review

References (133)

1. Hopkins DR. Smallpox entombed. Lancet 1985;1:175.
2. Littman RJ. The Athenian plague: Smallpox. Transactions and Proceedings of the American Philological Association 1969;261-75.
3. Behbehani AM. Rhazes: The original portrayer of smallpox. JAMA 1984;252:3156-9.
4. Ma B. Variolation: Pioneer of modem immunology. Zhonghua Yi Shi Za Zhi 1995;25:139-44.
5. Brines R. Two hundred years on: Jenner and the discovery of vaccination. Immunol Today 1996;17:203-4.
6. Baxby D. The genesis of Edward Jenner's Inquiry of 1798: Acomparison of the two unpublished manuscripts and the published version. Med Hist 1985;29:193-9.
7. rd Ed. London: DN Shury; 1801.
8. Pasteur L. The germ theory and its applications to medicine and surgery. Read before the French Academy of Sciences, 29 April 1878. Comptes Rendus de l'Académie des Sciences 1878;86:1037-43.
9. Henderson DA. Principles and lessons from the smallpox eradication programme. Bull World Health Organ 1987;65:535-46.
10. Barquet N, Domingo P. Smallpox: The triumph over the most terrible of the ministers of death. Ann Intern Med 1997;127:635-42.
11. Brilliant LB, Hodakevic LN. Certification of smallpox eradication. Bull World Health Organ 1978;56:722-33.
12. Breman JG, Arita I. The confirmation and maintenance of smallpox eradication. N Engl J Med 1980;303:1263-73.
13. Stanley MA. Human papillomavirus and cervical carcinogenesis. Best Practice and Research in Clinical Obstetrics and Gynecology 2001;15:663-76.
14. Liu JS, Kuo SR, Broker TR, Chow LT. The functions of human papillomavirus type 11 E1, E2 and E2c proteins in cell-free DNA replication. J Biol Chem 1995;270:27283-91.
15. Chow LT, Broker TR. Small DNA tumor viruses. In: Nathanson N, Ahmed R, Gonzelez-Scarano F, et al, editors. Viral Pathogenesis. Philadelphia: Lippincott-Raven; 1997. p. 267-301.
16. Crook T, Vousden KH. HPVoncoprotein function. In: Lacey C, editor. Papillomavirus Reviews: Current Research on Papillomaviruses. Leeds: Leeds University Press; 1996. p. 55-60.
17. Cullen AP, Reid R, Campion M, Lorincz AT. Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasm. J Virol 1961;65:606-12.
18. Man S, Fiander A. Immunology of human papillomavirus infection in lower genital tract neoplasia. Best Practice Res Clin Obstet Gynecol 2001;15:701-14.
19. Petry KU, Scheffel D, Bode U, Gabrysiak T, Kochel H, Kupsch E, et al. Cellular immunodeficiency enhances the progression of human papillomavirus-associated cervical lesions. Int J Cancer 1994;57:836-40.
20. Syrjanen KJ. Natural history of genital human papillomavirus infections. In: Lacey C, editor. Papillomavirus Reviews: Current Research on Papillomaviruses. Leeds: Leeds University Press, 1996. p. 189-206.
21. Röllinghoff M. Immunity, components of the immune system and immune response. Biologicals 1997;25:165-8.
22. Stem PL, Faulkner R, Veranes E, Davidson EJ. The role of human papillomavirus vaccines in cervical neoplasia. Best Practice and Research in Clinical Obstetrics and Gynecology 2001;15:783-99.
23. Hoffman JA, Kafatos FC, Janeway Jr CA, Ezekowitz RAB. Phylogenetic perspectives in innate immunity. Science 1999;284:1313-8.
24. Fearon DT. Innate immunity and the biological relevance of the acquired immune response. Q J Med 1999;92:235-7.
25. Modlin RB, Brightbill HD, Godowski PJ. The toll of innate immunity on microbial pathogens. N Engl J Med 1999;340:1834-5.
26. Palucka K, Banchereau J. Dendritic cells: A link between innate and adaptive immunity. J Clin Immunol 1999;19:12-25.
27. Hilleman MR. Overview of vaccinology with special reference to papillomavirus vaccines. J Clin Virol 2000;19:79-90.
28. Janeway CA. The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol Today 1992;13:11-6.
29. Matzinger P. Tolerance, danger and the extended family. Annu Rev Immunol 1994;12:991-1045.
30. Matzinger P. An innate sense of danger. Semin Immunol 1998;10:399-415.
31. Schiller JT. Papillomavirus-like particle vaccines for cervical cancer. Mol Med Today 1999;5:209-15.
32. Carter JJ, Koutsky LA, Wipf GC, et al. The natural history of human papillomavirus type-16 capsid antibodies among a cohort of university women. J Infect Dis 1996;174:927-36.
33. Garzetti GG, Ciavattini A, Buttini L, Vecchi A, Montroni M. Cervical dysplasia in HIV-seropositive women: Role of human papillomavirus infection and immune status. Gynecol Obstet Invest 1994;40:52-6.
34. Ozsaran AA, Ates T, Dikmen Y, Zeytinoglu A, Terek C, Erhan Y, et al. Evaluation of the risk of cervical intraepithelial neoplasia and human papillomavirus infection in renal transplant recipients receiving immunosuppressive therapy. Eur J Gynaecol Oncol 1999;20:127-30.
35. Stern PL, Brown M, Stacey SN, Kitchener HC, Hampson I, Abdel-Hady E-S, et al. Natural HPV immunity and vaccination strategies. J Clin Virol 2000;19:57-66.
36. Bamard P, McMillan NA. The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-alpha. Virology 1999;259:305-13,
37. Halpern AL. Comparison of papillomavirus and immunodeficiency virus evolutionary patterns in the context of a papillomavirus vaccine. J Clin Virol 2000;19:43-56.
38. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J Natl Cancer Inst 1995;87:796-802.
39. Chan SY, Ho L, Ong CK, Chow V, Drescher B, Durst M, et al. Molecular variants of human papillomavirus type 16 from four continents suggest ancient pandemic spread of the virus and its coevolution with humankind. J Virol 1992;66:2057-66.
40. Ho L, Chan SY, Chow V, Cong T, Tay SK, Villa LL, et al. Sequence variants of human papillomavirus type 16 in clinical samples permit verification and extension of epidemiological studies and construction of a phylogenetic tree. J Clin Microbiol 1991;29:1765-72.
41. Ong CK, Chan SY, Campo MS, Fujinaga K, Mavromara-Nazos P, Labropoulou V, et al. Evolution of human papillomavirus type 18: An ancient phylogenetic root in Africa and intratype diversity reflect coevolution with human ethnic groups. J Virol 1993;67:6424-31.
42. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6.
43. Frazer IH, Thomas R, Zhou J, Leggatt GR, Dunn L, McMillan N, et al. Potential strategies utilized by papillomaviruses to evade host immunity. Immunol Rev 1999;168:131-42.
44. Sharp PM, Bailes E, Robertson DL, Gao F, Hahn BH. Origins and evolution of AIDS viruses. Biol Bull 1999;196:338-42.
45. Bernard HU, Chan SY, Delius H. Evolution of papilomaviruses. Curr Top Microbiol Immunol 1994;186:33-54.
46. Tewari KS, Taylor JA, Liao SY, DiSaia PJ, Burger RA, Monk BJ, et al. Development and assessment of a general theory of cervical carcinogenesis utilizing a severe combined immunodeficiency murine-human xenograft model. Gynecol Oncol 2000;77:137-48.
47. Munoz N. Human papillomavirus and cancer: The epidemiological evidence. J Clin Virol 2000;19:1-5.
48. Meisels A, Fortin R. Condylomatous lesions of the cervix and vagina. I. Cytologic patterns. Acta Cytol 1976;20:505-9.
49. zur Hausen H. Viruses in human tumors: Reminiscences and perspectives. Adv Cancer Res 1996;68:1-22.
50. Gissmann L, de Villiers EM, zur Hausen H. Analysis of human genital warts (condyloma acuminata) and other genital tumors for human papillomavirus type 6 DNA. Int J Cancer 1982;29:143-6.
51. Gissmann L, Wolnik L, Ikenberg H, et al. Human papillomavirus types 6 and II DNA sequences in genital and laryngeal papillomas and in some cervical cancers. PNAS USA 1983;80:560-3.
52. Durst M, Gissmann L, Ikenberg H, zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. PNAS USA 1983;80:3812-5,
53. Boshart M, Gissmann L, Ikenberg H, et al. A new type of papillomavirus DNA: Its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO J 1984;3:1151-7.
54. Schwarz E, Freese UK, Gissmann L, et al. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature 1985;314:111-4.
55. zur Hausen H. Papillomaviruses in human cancers. Mol Carcinog 1988;1:147-50.
56. Sakula A. Robert Koch (1843-1910): Founder of the science of bacteriology and discoverer of the tubercle bacillus. A study of his life and work. Br J Dis Chest 1979;73:389-94.
57. Brinton LA. Epidemiology of cervical cancer overview. IARC Sci Publ 1992;119:3-23.
58. Shope RE. Infectious papillomatosis of rabbits. J Exp Med 1933;58:607-24.
59. Rous P, Beard JW. The progression to carcinoma of virus-induced rabbit papillomas. J Exp Med 1935;62:523-48.
60. Wallboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
61. Ho GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-8.
62. Koutsky LA, Holmes KK, Critchlow CW, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992;327:1272-8.
63. Remmink AJ, Wallboomers JIM, Helmerhorst TJ, et al. The presence of persistent high risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: Natural history up to 36 months. Int J Cancer 1995;61:306-11.
64. Liaw KL, Glass AG, Manos MM, et al. Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions. J Natl Cancer Inst 1999;91:954-60.
65. Herrero R, Hildesheim A, Bratti C, et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 2000;92:464-74.
66. Laara E, Day NE, Hakama M. Trends in mortality from cervical cancer in the Nordic countries: Association with organized screening programs. Lancet 1987;1:1247-9.
67. Sigurdsson K. Effect of organized screening on the risk of cervical cancer: Evaluation of screening activity in Iceland. Int J Cancer 1993;54:563-70.
68. MacGregor JE, Moss SM, Parkin DM, Day NE. A case control study of cervical cancer screening in the NE Scotland. BMJ 1985;290:1543-6.
69. Hakama M, Luohivuori K. A screening programme for cervical cancer that worked. Cancer Surv 1998;7:403-16.
70. Adams M, Borysiewicz L, Fiander A, Man S, Jasani B, Navabi H, et al. Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. Vaccine 2001;19:2549-56.
71. Gatta G, Lasota MB, Verdecchia A, and the Eurocare Working Group. Survival of European women with gynaecological tumours during the period 1978-1989. Eur J Cancer 1998;34:2218-25.
72. Gamett GP, Waddell HC. Public health paradoxes and the epidemiological impact of an HPV vaccine. J Clin Virol 2000;19:101-11.
73. Anderson RM, May RM. Infectious Diseases of Humans: Dynamics and Control. Oxford: Oxford University Press; 1991.
74. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. PNAS USA 1992;89:12180-4.
75. Rose RC, Reichman RC, Bonnez W. Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera. J Gen Virol 1994;75:2075-9.
76. Roden RBS, Greenstone HL, Kimbauer R, Booy FP, Jessie J, Lowy DR, et al. In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J Virol 1996;70:5875-83.
77. Unckell F, Streeck RE, Sapp M. Generation and neutralization of pseudovirions of human papillomavirus type 33. J Virol 1997;71:2934-9.
78. Thierry F, Yaniv M. Introduction: Human papillomavirus. Semin Cancer Biol 1996;7:307.
79. Donnelly JJ, Martinez D, Jansen KU, Ellis RW, Montgomery DL, Liu MA. Protection against papillomavirus with polynucleotide vaccine. J Infect Dis 1996;713:314-20.
80. Hines JF, Ghim S-J, Schlegel R, Jenson AB. Prospects for a vaccine against human papillomavirus. Obstet Gynecol 1995;86:860-6.
81. Frazer IH. Immunology of papillomavirus infection. Curr Opin Immunol 1996;8:484-91.
82. Galloway DA. Is vaccination against human papillomavirus a possibility? Lancet 1998;351:22-4.
83. Greenstone HL, Nieland JD, de Visser KE, Debruijn MLH, Kimbauer R, Roden RBS, et al. Chimeric papillomavirus-like particles elicit anti-tumor immunity against the E7 oncoprotein in an HPV 16 tumor model. PNAS USA 1998;95:1800-5.
84. Schiller JT. Papillomavirus-like particle vaccines for cervical cancer. Mol Med Today 1999;5:209-15.
85. Murakami M, Gurski KJ, Marincola F, Ackland J, Steller MA. Induction of specific CD3+ T-lymphocyte responses using a human papillomavirus-16 E6/E7 fusion protein and autologous dendritic cells. Cancer Res 1999;59:1184-7.
86. Murakami M, Gurski KJ, Steller MA. Human papillomavirus vaccines for cervical cancer. J Immunother 1999;22:212-8.
87. Paavonen J, Halttunen M, Hansson B-G, Nieminen P, Rostila T, Lehtinen M. Prerequisites for human papillomavirus vaccine trial: Results of feasibility studies. J Clin Virol 2000;19:25-30.
88. Osen W, Jochmus I, Müller M, Gissmann L. Immunization against human papillomavirus infection and associated neoplasia. J Clin Virol 2000;19:75-8.
89. Lehtinen M. Vaccinating women against premature death. J Clin Virol 2000;19:123-33.
90. Breitburd F, Kimbauer R, Hubbert NL, et al. Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995;69:3959-63.
91. Christensen ND, Krieder JW, Kan NC, DiAngelo SL. The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes. Virology 1991;181:572-9.
92. Kimbauer R, Chandrachud LM, O'Neil BW, Wagner ER, Grindlay GJ, Armstrong A, et al. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 1996;219:37-44.
93. Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, Bell JA, et al. Systematic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. PNAS USA 1995;992:11553-7.
94. Schiller JT, Hildesheim A. Developing HPV virus-like particle vaccines to prevent cervical cancer: A progress report. J Clin Virol 2000;19:67-74.
95. Harro CD, Pang YYS, Roden RBS, Hildesheim A, Wang Z, Reynolds MJ, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 2001;93:284-92.
96. th International Papillomavirus Conference. Barcelona, 2000.
97. th International Papillomavirus Conference. Barcelona, July 23-28, 2000.
98. th International Papillomavirus Conference. Barcelona, July 23-28, 2000.
99. Balsley JF, Connor EM, Reichman RC, Dubin G, Strouse RJ, Suzich JA, et al. Progress in the development of human papillomavirus vaccines for HPV-11 and HPV- 16/18 and mapping of a critical neutralizing epitope. Presented at the 18th International Papillomavirus Conference. Barcelona, July 23-28, 2000.
100. Schiffman M, Herrero R, Hildesheim A, Sherman ME, Bratti M, Wacholder S, et al. HPV DNA testing in cervical cancer screeing: Results from women in a high-risk province in Costa Rica. JAMA 2000;283:87-93.
101. Heyward WL, MacQueen KM, Goldenthal KL. HIV vaccine development and evaluation: Realistic expectations. AIDS Res Hum Retroviruses 1998;14:205-10.
102. Moore MA, Tsuda H. Cancer screening: An educational challenge? Eur J Cancer 1999;8:7-16.
103. Sherlaw-Johnson C, Gallivan S, Jenkins D. Evaluating cervical cancer screening programmes for developing countries. Int J Cancer 1997;72:210-6.
104. Da Silva DM, Eiben GL, Fausch SC, Wakabayashi MT, Rudolf MP, Velders MP, et al. Cervical cancer vaccines: Emerging concepts and developments. J Cell Physiol 2001;186:169-82.
105. Chen CH, Wang TL, Hung CF, Yang Y, Young RA, Pardoll DM, et al. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 2000;60:1035-42.
106. Potischman N, Brinton LA. Nutrition and cervical neoplasia. Cancer Causes Control 1996;7:113-26.
107. Rock CL. Carotenoids: Biology and treatment. Pharmacol Ther 1997;75:185-97.
108. Potischman N. Nutritional epidemiology of cervical neoplasia. J Nutr 1993;123:424-9.
109. Potischman N, Herrero R, Brinton LA, et al. A case-control study of nutrient status and invasive cervical cancer. Am J Epidemiol 1991;134:1347-55.
110. Brock KE, Berry G, Mock PA, et al. Nutrients in diet and plasma and risk of in situ cervical cancer. Journal of the National Cancer Institute (JNCI) 1988;80:580-5.
111. Wylie-Rosett JA, Romney SL, Slagle NS, et al. Influence of vitamin A on cervical dysplasia and carcinoma in situ. Nutr Cancer 1984;6:49-57.
112. Marshall JR, Graham S, Byers T, et al. Diet and smoking in the epidemiology of cancer of the cervix. J Natl Cancer Inst 1983;70:847-51.
113. Singh VN, Gaby SK. Premalignant lesions: Role of antioxidant vitamins and beta-carotene in risk reduction and prevention of malignant transformation. Am J Clin Nutr 1991;53:386S-90S.
114. Muto Y, Fujii J, Shidoji Y, et al. Growth retardation in human cervical dysplasia-derived cell lines by beta-carotene through down-regulation of epidermal growth factor receptor. Am J Clin Nutr 1995;62:6S.
115. De Vet HC, Knipschild PG, Willebrand D, et al. The effect of beta-carotene on the regression and progression of cervical dysplasia: A clinical experiment. J Clin Epidemiol 1991;44:273-83.
116. Romney S, Ho G, Palan P, et al. Effects of beta-carotene and other factors on outcome of cervical dysplasia and human papillomavirus infection. Gynecol Oncol 1997;65:484-92.
117. Mackerras D, Baghurst P, Fairley C, et al. Beta-carotene and cervical dysplasia trials in Australia. Ann N Y Acad Sci 1993;691:253-4.
118. Kelloff GJ, Johnson JR, Crowell JA, et al. Approaches to the development and marketing approval of drugs that prevent cancer. Cancer Epidemiol Biomarkers Prev 1995;4:1-10.
119. Butterworth Jr C, Hatch KD, Macaluso M, et al. Folate deficiency and cervical dysplasia. JAMA 1992;267:528-33.
120. Childers J, Chu J, Voigt L, et al. Chemoprevention of cervical cancer with folic acid: A phase III Southwest Oncology Group Intergroup study. Cancer Epidemiol Biomarkers Prev 1995;4:155-9.
121. Kim YI, Pogribny IP, Basnakian AG, et al. Folate deficiency in rats induces DNA strand breaks and hypomethylation within the p53 tumor suppressor gene. Am J Clin Nutr 1997;65:46-52.
122. Butterworth CE. Effect of folate on cervical cancer: Synergism among risk factors. Ann N Y Acad Sci 1992;669:293-9.
123. Meydani SN, Meydani M, Blumberg JB, et al. Vitamin E supplementation and in vivo immune response in healthy elderly subjects: A randomized controlled trial. JAMA 1997;277:1380-6.
124. Steinmetz KA, Potter JD. Vegetables, fruit and cancer prevention: A review. J Am Diet Assoc 1996;96:1027-39.
125. Rock CL, Michael CW, Reynolds RK, Ruffin MT. Prevention of cervix cancer. Crit Rev Oncol Hematol 2000;33:169-85.
126. Sporn MB, Dunlop NM, Newton DL, et al. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 1976;35:1332-8.
127. Shureiqi I, Reddy P, Brenner DE. Chemoprevention: General perspective. Crit Rev Oncol Hematol 2000;33:137-67.
128. Bertram JS, Kolonel LN, Meyskens Jr FL. Rationale and strategies for chemoprevention of cancer in humans. Cancer Res 1987;47:3012-31.
129. Boone CW, KelloffGJ, Malone WE. Identification of candidate cancer chemopreventive agents and their evaluation in animal models and human clinical trials: A review. Cancer Res 1990;50:2-9.
130. Weinstein IB, Cancer prevention: Recent progress and future opportunities. Cancer Res 1991;51:5080S-5S.
131. Meyskens FL, Surwitz E, Moon TE, et al. Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: A randomized trial. J Natl Cancer Inst 1995;86:539-43.
132. Nishioka K, Melgaregjo AB, Lyon RR, et al. Polyamines as biomarkers of cervical intraepithelial neoplasia. J Cell Biochem 1995;23:87S-95S.
133. Boiko I, Mitchell M, Pandey D, et al. DNA image cytometric measurement as a surrogate endpoint biomarker in a phase I trial of alpha difluoromethylomithine for cervical intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev 1997;6:849-55.